Managing Short Methadone Half-life in the Perinatal Period: A Case Report of a Patient Requiring 900 mg Daily

Using serum methadone levels to calculate methadone clearance can help providers individualize dosing, particularly in patients displaying clinical symptoms of rapid clearance, such as peak sedation with concomitant trough withdrawal. Multiple factors may impact methadone dose requirements and serum levels, necessitating deviation from standard methadone titration protocols. The physiologic changes of pregnancy generally shorten methadone's half-life due to CYP450 enzyme induction and increased volume of distribution. Additionally, the emergence of fentanyl-a far more potent opioid than its predecessors-has led to increased opioid tolerance among individuals who use it. As a result, these individuals may require higher methadone doses to effectively manage their opioid dependence. We present a case of a pregnant patient with opioid use disorder, primarily using fentanyl, who presented to labor and delivery at 36 weeks 6 days of gestation. She delivered at 37 weeks 1 day and remained admitted for 4 weeks while undergoing methadone induction. At the time of discharge, she endorsed ongoing opioid withdrawal and required ongoing methadone dose escalation at her outpatient methadone clinic after discharge. Laboratory testing one month postpartum indicated a methadone half-life of 9.22, and she was determined to need thrice daily dosing to maintain therapeutic serum levels, with her total daily dose ultimately reaching 300 mg 3 times daily. In patients who do not respond to standard methadone titration protocols, laboratory testing can support individualized dosing strategies to achieve therapeutic levels while maintaining patient safety.